Last updated on August 2019

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Early [Prodromal to Mild] Alzheimer's Disease


Brief description of study

Studies the effect of a new drug in Early Alzheimer's

Clinical Study Identifier: TX227902

Find a site near you

Start Over

Via Christi Research

1100 N St Francis, Suite 300 Wichita, KS USA
  Connect »